Condition: Acute Myeloid Leukemia · Acute Myeloid Leukemia Refractory · Acute Myeloid Leukemia, in Relapse · Sponsor: Seattle Children's Hospital
A phase 1, open-label, non-randomized study enrolling pediatric and young adult patients with relapsed or refractory CD33+ leukemia with and without prior history of allogeneic hematopoietic cell transplantation, to examine the safety and feasibility of administering an autologous T cell product that has been genetically modified to express a Dimerizing Agent Regulated Immunoreceptor Complex (DARIC).
This description comes directly from the study's public registry record.
Adam Lamble, MD · 206-986-2106 · CBDCIntake@seattlechildrens.org
Always discuss trial participation with your own doctor first.
| Seattle Children's Hospital | Seattle, Washington, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05105152